Accommodating intraocular lenses
Accommodating intraocular lenses
复制标题
DOI：
10.1097/00055735-200402000-00004
复制
发表时间：
2004-02
影响因子：
3.7
通讯作者：
J. Doane
中科院分区：
文献类型：
--
作者：
J. Doane
综述目的随着人们对可调节镜片作为老花眼和婴儿潮一代人口增长的解决方案的兴趣的出现，眼科外科医生将有机会提供这项技术来促进他们的患者的近、中、远视力。最新发现目前，六家公司实体和晶状体设计公司正试图将可调节人工晶状体设备商业化。食品和药物管理局(FDA)的一项临床试验已经完成，第一个FDA批准的调节晶状体已经上市。总结：眼科外科医生将首次能够为患者的每只眼睛提供全方位的视觉焦点，以维持双眼功能，同时还可以避免使用单视和多焦点透镜技术所经历的不必要的中间视觉和暗视视觉干扰。可调节人工晶状体不仅可以彻底改变白内障的视力康复，而且还可以改变老花眼的手术方式。
Purpose of review With the advent of interest in accommodative lenses as a solution for presbyopia and the growing baby-boomer demographic, ophthalmic surgeons will have the opportunity to provide this technology to facilitate near, intermediate, and distance vision for their patients. Recent findings At present, six corporate entities and lens designs are attempting to commercialize accommodative intraocular lens devices. One Food and Drug Administration (FDA) clinical trial has been completed and the first FDA-approved accommodating lens is available. Summary For the first time, ophthalmic surgeons will be able to provide a full range of visual focus in each eye of a patient to maintain binocular function while also avoiding the unwanted mesopic and scotopic visual disturbances that are experienced with monovision and multifocal lens technologies. Accommodative intraocular lenses could revolutionize not only cataract visual rehabilitation but also the surgical approach to presbyopia.